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efficacy-evaluable (EE), IAI patients who received piper-
acillin/tazobactam (pip/tazo, 4g/500 mg) or imipenem/
cilastatin (imip/cil, 1g/1g) q8 hr by slow infusion in a
randomized, double blind study. Baseline severity was
evaluated using the APACHE II scoring system. Clinical
and bacteriological efficacy was similar across treatment
groups. A Cox proportional hazards analysis was used to
estimate TTD adjusting for APACHE II scores. RE-
SULTS: Baseline APACHE II scores were higher in the
pip/tazo group than the imip/cil group for the intent-to-
treat population (P  0.04) and EE population (P 
0.07). The pip/tazo group had a 23% lower instanta-
neous rate of hospital discharge (IRHD) compared to the
imip/cil group (relative odds  0.77; P  0.04). Severity
adjustment using the APACHE II indicated that treat-
ment-related differences in IRHD were not different (P 
0.12). APACHE II independently predicted TTD; a 1-point
increase in APACHE II score was associated with a 6%
lower IRHD (relative odds  0.94; P  0.001). Pip/tazo
patients were treated for IAI for an average of 7.6 days
compared to 7.1 days for imip/cil patients. Combining
daily average wholesale price (imip/cil $169.89 vs. pip/
tazo $64.26) and equivalent administration costs resulted
in a saving of $718 per course of therapy. CONCLU-
SIONS: Treatment with pip/tazo is equivalent to imip/cil
in terms of efficacy, duration of treatment and APACHE
II-adjusted hospital length-of-stay for IAI, but cost saving
due to lower acquisition costs.
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Advances in technology and surgical methods have al-
lowed an increasing number of surgical procedures to be
performed on an ambulatory basis, which has improved
patient outcomes and decreased the costs associated with
many of these procedures. Unfortunately, an area that
continues to exhibit negative clinical and economic con-
sequences is postoperative nausea and vomiting (PONV).
The prevalence of PONV after general anesthesia, even
for those surgeries performed on an ambulatory basis, re-
mains quite high and is a leading cause of delayed dis-
charge and unanticipated hospitalization in these pa-
tients. OBJECTIVE: To test the efficacy, safety, and
economic impact of an algorithm for PONV prophylaxis.
METHODS: From October to December 1999, baseline
data were collected on 473 consecutive patients undergo-
ing surgical procedures of any kind, including demo-
graphic data, risk factors for PONV, medication utiliza-
tion, occurrence of PONV, time in PACU, unanticipated
hospitalization, and patient satisfaction. Following im-
plementation of a PONV prophylaxis algorithm, data
will be collected for consecutive patients undergoing sur-
gical procedures and compared to the data from the base-
line period. RESULTS: Preliminary analysis of the base-
line data found that 34 of 473 patients (7.2%) had at
least one episode of emesis in the PACU. Thirteen of
these patients (38.2%) were delayed from being dis-
charged secondary to PONV; average time spent in the
PACU was 41 minutes for patients without PONV and
130 minutes for patients with PONV. Three patients
were hospitalized for PONV. CONCLUSION: Compari-
son of data before and after implementation of the dolas-
etron-based algorithm will allow us to determine the effi-
cacy, safety, and economic impact.
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Pharmacists have opportunities to provide cost savings in
an intensive care unit (ICU) by identifying potential
sources of errors. Due to the high intensity of drug costs,
a clinical pharmacist was placed in the ICU with the role
to evaluate drug utilization and identify potential oppor-
tunities to decrease costs while maintaining positive pa-
tient outcomes. OBJECTIVE: This pilot project evaluates
a pharmacist intervention program targeting antibiotic
cost reduction in a community hospital ICU. METH-
ODS: Pharmacist interventions include, but are not lim-
ited to, antibiotic streamlining, intravenous to oral switch,
total parenteral nutrition consults, pharmacokinetic con-
sults, dosage adjustments, identification of drug interac-
tions, and eliminating therapy duplications. Drug utilization
and drug cost for the ICU and the entire hospital (exclud-
ing the ICU and nursery), were calculated monthly and
included the total number of units dispensed, total drug
cost, drug cost per patient day, and units dispensed per
patient day. Outcomes for monitored antibiotics were
compared between the hospital and the ICU, as well as
before and after the clinical pharmacist intervention pro-
gram was initiated. RESULTS: Data is presented from
July 1999 to November 1999, with initiation of the inter-
vention being performed from August 1999. The average
antibiotic cost per ICU patient day was higher, $36.43,
as compared to overall hospital antibiotic cost per patient
day of $20.80. Mean antibiotic costs for the ICU decreased
significantly following the interventions and were as fol-
lows: July: $42.27; August, $36.99; September, $39.92;
October, $37.69; and November, $37.59. Average monthly
antibiotic units dispensed for the hospital were 5077
(1.59 units/patient day) and for the ICU were 817 (2.66
units/ICU patient day). The total number of pharmacist
interventions averaged 49 per month. No adverse patient
outcomes were reported during this period. CONCLU-
SION: We continue to monitor the effectiveness of a clin-
ical pharmacist in the ICU by monitoring drug utiliza-
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tion, drug cost, and therapeutic outcomes. Although
additional data is required for conclusive evidence, the
preliminary data suggests a downward trend in antibiotic
costs in the ICU.
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INTRODUCTION: The impact of prescription NSAIDS
on the GI tract is well documented. The easy availability
of low-dose OTC NSAIDs may lead to iatrogenic GI dis-
ease invisible to the medical community. OBJECTIVE:
To determine if the role and rate of GI adverse side ef-
fects were related to over-the-counter NSAID use. METH-
ODS: Data were obtained by structured telephone survey
administered to a nationally representative, randomly se-
lected US adult population (40 years). We compared re-
sponses of regular OTC NSAID users (defined as use for
at least 4 of 7 days, and 16 of 30 days prior to the sur-
vey) with those of non-users. Logistic regression com-
pared the likelihood of GI symptoms and use of GI med-
ications, after adjusting for age, gender, ethnicity, and
self-reported health status. RESULTS: We surveyed 535
OTC NSAID users (mean age  63, range 40–96) and
1068 non users (mean age  63, range 40–93). NSAID
users were 2.1 times more likely to report GI symptoms
than non users (P  0.0001), and 2.7 times more likely
to have taken OTC GI medications than non users (P 
0.0001) during past 30 days. 84.8% of NSAID users tak-
ing GI medications for their symptoms had not informed
a physician of GI symptoms. CONCLUSIONS: OTC
NSAIDs are widely used and thought to be safe at low
dose. Our data show users commonly experience GI
symptoms, for which they self-medicate without inform-
ing their physician. This may represent an important bur-
den of hidden GI disease.
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Peptic ulcers, erosions of the stomach lining, afflict greater
than 25 million Americans. Ulcers diminish quality of life
and cost nearly $6 billion dollars annually. OBJECTIVE:
To decrease unnecessary medical utilization, histamine-2-
blocker (H2) and proton-pump-inhibitor (PPI) utilization
and improve quality of life for peptic ulcer patients by us-
ing educational intervention to increase compliance to
drug regimens for H. pylori eradication. METHODS: Pa-
tients were targeted for specific antibiotic therapies via
drug data and verified at first telephone contact. A ques-
tionnaire developed and validated by Lewin-TAG was
used for data collection. Data were collected for a 90 day
period pre/post therapy regarding hospitalizations, doc-
tor visits, emergency room visits, lost productivity, out-
patient surgeries, pharmacy utilization and medical test/
procedures resulting from the disease. Quality of life
questions measured how often usual activities and work
productivity were reduced due to peptic ulcer disease. Pa-
tient satisfaction with the program was also measured.
RESULTS: (n  1993, response rate  94.5%) Patient
compliance to drug regimen was found to be 95.7%.
Hospitalizations were reduced by 73% (P  0.0001),
doctor visits by 49% (P  0.0001). Emergency room vis-
its were reduced by 72% (P  0.0001) and outpatient
surgeries by 56% (P  0.0001). Finally, a decrease of
54% in H2/PPI usage (P  0.0001) and a decrease of
76% in medical tests/procedures (P  0.0001) were seen.
Participants reported a 13% decrease in pain and symp-
toms (P  0.005) and a 34% increase in productivity
(P  0.0001). Participant satisfaction rate with the pro-
gram was 98.6%. CONCLUSION: The CarePatterns
peptic ulcer disease program improves patients’ quality
of life, reduces unnecessary medical and pharmacy utili-
zation, and is cost-effective.
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OBJECTIVE: The aim of this project is to evaluate the ef-
fectiveness of a program including practice guidelines,
treatment algorithms, and peer comparison feedback in
changing physicians’ prescribing behaviors in the treat-
ment of patients with peptic ulcer disease (PUD). METH-
ODS: A prospective intervention with a control group
was conducted to determine the impact of a PUD infor-
mation dissemination program targeted towards physi-
cians in a managed care setting. Pharmacy claims data
were used to assess impact of the program on utilization
of eradication therapy, long-term antisecretory utiliza-
tion, and total cost of drug therapy per patient. RE-
SULTS: Preliminary data from a 3-month follow-up pe-
riod are available and indicate that utilization of eradication
